Ginkgo Bioworks
DNA
DNA
320 hedge funds and large institutions have $1.68B invested in Ginkgo Bioworks in 2022 Q4 according to their latest regulatory filings, with 88 funds opening new positions, 119 increasing their positions, 57 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
0.02% more ownership
Funds ownership: 1.84% → 1.86% (+0.02%)
39% less capital invested
Capital invested by funds: $2.74B → $1.68B (-$1.06B)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
320
Holding in Top 10
2
Calls
$11.4M
Puts
$6.83M
Top Buyers
| 1 | +$67.8M | |
| 2 | +$41.3M | |
| 3 | +$29.7M | |
| 4 |
BlackRock
New York
|
+$27M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.4M |
Top Sellers
| 1 | -$65.5M | |
| 2 | -$9.36M | |
| 3 | -$5.34M | |
| 4 |
TCM
Trybe Capital Management
Greenwich,
Connecticut
|
-$3.29M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.91M |